Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

Area of Science:

• Immunology
• Allergy Research
• Cell Biology

Background:

• Dendritic cells (DCs) are key antigen-presenting cells expressing the high-affinity IgE receptor (FcepsilonRI).
• While omalizumab's effect on basophil FcepsilonRI is known, its impact on DCs remains uninvestigated.

Purpose of the Study:

• To test if IgE regulates DC FcepsilonRI expression in vivo.
• To determine if anti-IgE therapy reduces DC FcepsilonRI expression.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 24 subjects with allergic rhinitis.
• Analysis of precursor DC1 (pDC1) and pDC2 FcepsilonRIalpha expression via flow cytometry in serial blood samples.
• Treatment involved omalizumab or placebo on days 0 and 28, with sample collection on days 0, 7, 14, 28, and 42.

Main Results:

• Omalizumab significantly decreased FcepsilonRI expression on both pDC1 and pDC2 subsets at all time points.
• Placebo showed no significant changes in FcepsilonRI expression.
• Maximum FcepsilonRI reduction was 52% (pDC1) and 83% (pDC2) with omalizumab, correlating with decreased serum-free IgE.

Conclusions:

• Anti-IgE therapy rapidly reduces DC FcepsilonRI surface expression.
• IgE is confirmed as a significant regulator of FcepsilonRI expression on dendritic cells.